Navigating the CARES Act for Life Sciences Companies in the BioHealth Capital Region webinar
Please join DLA Piper and BioHealth Innovation, Inc. (BHI) as we present an overview of the key provisions for BioHealth Capital Region Life Sciences companies in the $2 trillion Coronavirus Aid, Relief, and Economic Security Act stimulus package. Register today for this FREE webinar on Friday, April 3rd.
Milwaukee County Employees' Retirement System committed a total of $80 million to Baring Private Equity Asia, Barings, Fairview Capital Partners and Greenspring Associates to manage in private equity fund-of-funds portfolios.
The $1.7 billion pension fund's board on Feb. 26 approved hiring Barings, BPEA, Fairview and Greenspring to run portfolios of about $28 million, $30 million, $12 million and $10 million, respectively, recently released meeting minutes show.
We will beat the COVID19 virus, and innovation will play a key role in that victory. We will find new treatments, using either new drugs, or hopefully fast-tracking reapplication of existing ones. We will reapply existing technology to mass produce respirators. Nothing spurs innovation like a crisis, or a war, and we are in the middle of both.
For over two centuries, New York has been the predominant urban center in North America. It remains the primary locale for the arts, culture, finance, and media, and will likely remain so for the foreseeable future. It has also served as the incubator of the many Americas—including Jewish, Italian, African American, Irish, and, increasingly, Middle Eastern, North African, and Asian cultures—and nurtured their contributions to the arts, business, and intellectual life.
Far too many organizations miss golden opportunities to bring onboard best possible talent for the tasks at hand — and those of the future. When it’s time to recruit, hire, and onboard, the most common approaches are routine and rote, prone to misjudgment and error. The process is costly and, in the end, unfruitful.
Unfortunately, many entrepreneurs seem to prefer to fail their way to the top, rather than do some research and learn from the successes and mistakes of others. It seems to be part of the “fail fast, fail often” mantra often heard in Silicon Valley. As an advisor to many startups, I’m convinced it’s an expensive and painful approach, but I do see it used all too often.
The Food and Drug Administration has granted an emergency use authorization to a drug for treating Covid-19, although there is little evidence so far to demonstrate that it works.
In a letter Saturday to Rick Bright, director of the Department of Health and Human Services’ Biomedical Advanced Research and Development Authority, FDA chief scientist Denise Hinton wrote that the agency had granted Bright’s request for an EUA for oral formulations of hydroxychloroquine sulfate and chloroquine phosphate, two closely related malaria drugs that have been tested as treatments for Covid-19.
Image: A pharmacy employee in Paris holds up a box of chloroquine
Suspended near the bottom of the Mediterranean Sea off France and Italy, 126 football-sized glass spheres are already using the ocean itself as an instrument to search for signals from dark matter, supernovae and neutron star collisions. These are the first of many such globes deployed for a project called the Cubic Kilometer Neutrino Telescope, or KM3NeT.
Image: Researchers are in the process of deploying modules for a new pair of underwater telescopes (visualized here). Credit: KM3NET
The rapid spread of the novel coronavirus has sent governments, markets, and communities worldwide on a fervid search for answers—how long, how many, how much? Investors, too, are seeking facts about, among other things, how the global pandemic is affecting business operations, what companies are doing to protect employees and suppliers, what companies’ recovery plans entail, and whether companies have enough liquidity to withstand the pandemic. The markets are volatile, so companies’ responses to these queries could carry considerable weight with critical intrinsic investors and materially affect companies’ recovery plans and capitalization. To address investors’ immediate concerns and reset their expectations, CFOs and other senior business leaders should be prepared to answer the following questions.
Existing COVID-19 tests have a terrible user experience. You have to wait in line, sometimes for hours, to get one. If you’re getting tested, you probably already feel quite ill. And then you may have to wait hours, even days, for results.
Several companies are working on improved tests. Abbott Labs developed a five-minute screener for clinics that works on-site without sending samples to a lab. Cue Health is working on a 25-minute nasal swab test. And now, the Los Angeles-based company Scanwell Health is developing an at-home test kit for SARS-CoV-2, the virus that causes COVID-19.
Image: courtesy Scanwell Health
Three federal agencies have teamed up to collectively leverage and accelerate 3D printing and other advanced manufacturing technologies in the fight against COVID-19.
The Food and Drug Administration, Veterans Affairs Department and National Institutes of Health recently signed a Memorandum of Understanding to formalize a unified effort through which they’ll solicit designs for, produce and test 3D-printed personal protective equipment and other medical supplies to support America’s response to the worldwide health emergency.
During the great plague of 1665, Isaac Newton made the most of his year of social distancing. While forced to be away from Cambridge, he famously discovered the laws of gravity, conducted groundbreaking experiments in optics and began to develop the fundamentals of differential calculus.